PMID- 35571082
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - The Natural Product Andrographolide Ameliorates Calcific Aortic Valve Disease by 
      Regulating the Proliferation of Valve Interstitial Cells via the MAPK-ERK 
      Pathway.
PG  - 871748
LID - 10.3389/fphar.2022.871748 [doi]
LID - 871748
AB  - Calcific aortic valve disease (CAVD) is an active pathobiological process that 
      involves fibrosis and calcification of aortic valve leaflets, thereby causing 
      cardiac hemodynamic changes and eventually heart failure. Cell proliferation 
      changes at the initial stage of CAVD are an important target for pharmaceutical 
      intervention. This study aimed to investigate whether andrographolide (AGP) could 
      inhibit the proliferation of valve interstitial cells (VICs) in vitro and in vivo 
      to delay the process of CAVD. Cell proliferative factors were tested in both 
      healthy and CAVD aortic valve samples. Cell cycle, cell growth, and calcification 
      of VICs were assessed using flow cytometry, CCK8 assay, EdU staining, and 
      Alizarin Red S staining. The expression of cell proliferative factors and 
      osteogenic factors were quantified by qRT-PCR or immunofluorescence staining. The 
      interaction between AGP and ERK (extracellular regulated protein kinases) was 
      detected by molecular docking. In addition, a high-fat diet-fed animal model was 
      used to verify the effect of AGP on CAVD in vivo. In conclusion, we found that 
      AGP ameliorates aortic valve incrassation by inhibiting cell proliferation via 
      the MAPK-ERK signaling pathway. Therefore, AGP is a promising drug that prevents 
      the occurrence of CAVD via regulating cell proliferation.
CI  - Copyright (c) 2022 Huang, Liu, Liu, Dong and Chen.
FAU - Huang, Yuming
AU  - Huang Y
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Liu, Ming
AU  - Liu M
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
FAU - Liu, Chungeng
AU  - Liu C
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
FAU - Dong, Nianguo
AU  - Dong N
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
FAU - Chen, Liang
AU  - Chen L
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20220429
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9100698
OTO - NOTNLM
OT  - CAVD
OT  - MAPK /ERK2 pathway
OT  - andrographolide
OT  - cell proliferation
OT  - valve interstitial cell
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/05/17 06:00
MHDA- 2022/05/17 06:01
PMCR- 2022/04/29
CRDT- 2022/05/16 03:54
PHST- 2022/02/08 00:00 [received]
PHST- 2022/03/28 00:00 [accepted]
PHST- 2022/05/16 03:54 [entrez]
PHST- 2022/05/17 06:00 [pubmed]
PHST- 2022/05/17 06:01 [medline]
PHST- 2022/04/29 00:00 [pmc-release]
AID - 871748 [pii]
AID - 10.3389/fphar.2022.871748 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Apr 29;13:871748. doi: 10.3389/fphar.2022.871748. 
      eCollection 2022.